Humana (HUM) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
6 Mar, 2026Executive summary
Annual Meeting scheduled for April 16, 2026, at 1:00 p.m. ET via live webcast for shareholder participation.
Voting materials, including the proxy statement and annual report, are available online or by request, with voting open until April 15, 2026, at 11:59 p.m. ET.
Record date for voting eligibility is February 27, 2026; shareholders and 401(k) plan participants can vote on all proposals.
Voting matters and shareholder proposals
Election of ten directors is up for shareholder vote, with all nominees recommended by the board.
Ratification of PricewaterhouseCoopers LLP as independent auditor is recommended for approval.
Advisory vote on executive compensation (say-on-pay) is recommended for approval.
Approval of the 2026 Stock Incentive Plan is recommended.
Shareholder proposal to require approval for excessive golden parachutes is not recommended by the board.
Board of directors and corporate governance
Board recommends all director nominees for election at the annual meeting.
Proxies are authorized to vote on any other matters that may arise at the meeting.
Latest events from Humana
- Q2 2026 net income and revenues rose on Medicare and MaxHealth growth; guidance affirmed.HUM
Q2 2026 - Revenue up 23.5% to $39.6B; Adjusted EPS $10.31; robust Medicare growth; higher benefit costs.HUM
Q1 2026 - Director elections, strategic transformation, and all board proposals passed except golden parachutes.HUM
AGM 2026 - Margin targets, quality membership growth, and strategic acquisitions drive long-term outlook.HUM
Leerink Global Healthcare Conference 2026 - Proxy covers director elections, executive pay, new stock plan, and ESG priorities.HUM
Proxy Filing - Annual meeting covers director elections, compensation, new equity plan, and ESG progress.HUM
Proxy Filing - 2025 adjusted EPS reached $17.14; 2026 targets at least $9.00 EPS and 25% MA growth.HUM
Q4 2025 - Net income declined 29% as higher Medicare Advantage costs offset strong revenue growth.HUM
Q2 2024 - Q1 2025 net income and EPS surged; FY 2025 Adjusted EPS guidance reaffirmed at $16.25.HUM
Q1 2025